Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trials

被引：0
|
作者：
Herbel, N. [1 ]
Ouali, K. [1 ]
Danlos, F-X. [1 ]
Massard, C. P. [1 ]
Goldschmidt, V. [1 ]
Michot, J-M. [1 ]
Laparra, A. [2 ]
Bernard-Tessier, A. [3 ]
Gazzah, A. [1 ]
Bahleda, R. [1 ]
Hollebecque, A. [1 ]
Henon, C. [1 ]
Postel-Vinay, S. [1 ]
Loriot, Y. [1 ]
Ribrag, V. [1 ]
Marabelle, A. [1 ]
Fizazi, K. [3 ]
Aix, S. Ponce [1 ]
Champiat, S. [1 ]
Baldini, C. [1 ]
机构：
[1] Inst Gustave Roussy, Drug Dev Dept, Villejuif, France
[2] Inst Gustave Roussy, DIOPP, Villejuif, France
[3] Gustave Roussy Canc Campus, Med Oncol Dept, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.723
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
657P
引用
收藏
页码：S519 / S519
页数：1
相关论文
共 50 条
  • [41] Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)
    Bigot, Frederic
    Castanon, Eduardo
    Baldini, Capucine
    Hollebecque, Antoine
    Calmona, Alberto
    Postel-Vinay, Sophie
    Angevin, Eric
    Armand, Jean-Pierre
    Ribrag, Vincent
    Aspeslagh, Sandrine
    Varga, Andrea
    Bahleda, Rastislav
    Menis, Jessica
    Gazzah, Anas
    Michot, Jean-Marie
    Marabelle, Aurelien
    Soria, Jean-Charles
    Massard, Christophe
    EUROPEAN JOURNAL OF CANCER, 2017, 84 : 212 - 218
  • [42] ZW38, a Novel Azymetric Bispecific CD19-Directed CD3 T Cell Engager Antibody Drug Conjugate with Controlled T Cell Activation and Improved B Cell Cytotoxicity
    Ng, Gordon
    Spreter, Thomas
    Davies, Rupert
    Wickman, Grant
    BLOOD, 2016, 128 (22)
  • [43] Microenvironment-responsive anti-PD-L1 x CD3 bispecific T-cell engager for solid tumor immunotherapy
    Liu, Dingkang
    Bao, Lichen
    Zhu, Haichao
    Yue, Yali
    Tian, Jing
    Gao, Xiangdong
    Yin, Jun
    JOURNAL OF CONTROLLED RELEASE, 2023, 354 : 606 - 614
  • [44] Nonshrinkable Thermosensitive Hydrogels Combined with Bispecific Anti-PSMA/CD3 T-Cell Engager for Effective Against Tumors in Mice Model
    Wei, Pu-Sheng
    Chou, Po-Yu
    Hsu, Hao-Yi
    Chen, Michael
    Chen, Yi-Jou
    Tsai, Tung-Han
    Wen, Bang-Yu
    Sheu, Ming-Thau
    Chuang, Kuo-Hsiang
    Lin, Hong-Liang
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2025, 20 : 3083 - 3111
  • [45] Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies
    Kapetanovic, Edo
    Weber, Cedric R.
    Bruand, Marine
    Poschl, Daniel
    Kucharczyk, Jakub
    Hirth, Elisabeth
    Dietsche, Claudius
    Khan, Riyaz
    Wagner, Bastian
    Belli, Olivier
    Vazquez-Lombardi, Rodrigo
    Castellanos- Rueda, Rocio
    Di Roberto, Raphael B.
    Kalinka, Kevin
    Raess, Luca
    Ly, Kevin
    Rai, Shivam
    Dittrich, Petra S.
    Platt, Randall J.
    Oricchio, Elisa
    Reddy, Sai T.
    NATURE BIOMEDICAL ENGINEERING, 2024, 8 (12): : 1665 - 1681
  • [46] Generation of a novel ROR1 x CD3 bispecific T-cell engager for better tumor killing and minimal cytokine release
    Wu, Danqing
    Gong, Shiyong
    Wu, Xuan
    Naren, Gaowa
    Dong, Liqin
    Lensky, Stephan
    Wu, Chengbin
    CANCER RESEARCH, 2024, 84 (07)
  • [47] CD3 x CD28 cross-interacting bispecific antibodies improve tumor cell dependent T-cell activation
    Willems, A
    Schoonooghe, S
    Eeckhout, D
    De Jaeger, G
    Grooten, J
    Mertens, N
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (11) : 1059 - 1071
  • [48] Enhanced cytotoxicity in multiple myeloma via T cells armed with bispecific T cell engager targeting B-cell maturation antigen on cancer cells and CD3 on T cells
    Supimon, Kamonlapat
    Sangsuwannukul, Thanich
    Luangwattananun, Piriya
    Yenchitsomanus, Pa-thai
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 143
  • [49] A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells
    Riillo, Caterina
    Caracciolo, Daniele
    Grillone, Katia
    Polera, Nicoletta
    Tuccillo, Franca Maria
    Bonelli, Patrizia
    Juli, Giada
    Ascrizzi, Serena
    Scionti, Francesca
    Arbitrio, Mariamena
    Lopreiato, Mariangela
    Siciliano, Maria Anna
    Sestito, Simona
    Talarico, Gabriella
    Galea, Eulalia
    Galati, Maria Concetta
    Pensabene, Licia
    Loprete, Giovanni
    Rossi, Marco
    Ballerini, Andrea
    Gentile, Massimo
    Britti, Domenico
    Di Martino, Maria Teresa
    Tagliaferri, Pierosandro
    Tassone, Pierfrancesco
    CANCERS, 2022, 14 (12)
  • [50] Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3+tumors: Focus on Asian pts
    Kuboki, Y.
    Gambardella, V.
    Capdevila Castillon, J.
    Alese, O. B.
    Morgensztern, D.
    Sayehli, C. M.
    Sanmamed, M. F.
    Arriola, E.
    Wolf, J.
    Owonikoko, T. K.
    Studeny, M.
    Bouzaggou, M.
    Song, E.
    Wermke, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1495 - S1495
12345